13 results
SC TO-T
EX-99
TAK
Takeda Pharmaceutical Co
30 Apr 18
Third party tender offer statement
6:13am
dislocation, reputational harm or adverse market reaction) that may be suffered by Takeda equal to:
two million seven hundred thousand Euros (EUR … opportunity costs, increased costs for obtaining additional financing, business dislocation, reputational harm or adverse market reaction) that may
424B3
TAK
Takeda Pharmaceutical Co
14 Nov 19
Prospectus supplement
6:10am
in reputational damage.
Any of the above may reduce sales, delay the launch of new products, and adversely affect our business, financial condition … ) and regulations can be costly; any failure to comply with these regulatory standards could subject us to legal and reputational risks. Misuse
F-4
TAK
Takeda Pharmaceutical Co
9 Aug 19
Registration of securities (foreign)
6:27am
to us or result in reputational damage.
Any of the above may reduce sales, delay the launch of new products, and adversely affect our business … for under GDPR) and regulations can be costly; any failure to comply with these regulatory standards could subject us to legal and reputational risks
F-4/A
TAK
Takeda Pharmaceutical Co
12 Nov 19
Registration of securities (foreign) (amended)
9:50am
in reputational damage.
Any of the above may reduce sales, delay the launch of new products, and adversely affect our business, financial condition … ) and regulations can be costly; any failure to comply with these regulatory standards could subject us to legal and reputational risks. Misuse
20-F
2t99k
27 Jun 19
Annual report (foreign)
6:41am
20FR12B/A
1wv6yw14nj7qk2qho
17 Dec 18
Initial registration of securities (foreign private issuers) (amended)
6:14am
DRS/A
o9rez
16 Nov 18
Draft registration statement (amended)
12:00am
6-K
EX-99.1
o83 w2ltb6sth
17 Dec 20
Current report (foreign)
6:01am
20FR12B
o588j5b5rnys9o
6 Dec 18
Initial registration of securities (foreign private issuers)
10:39am
- Prev
- 1
- Next